Skip to main content
. 2022 Mar 17;32(3):273–282. doi: 10.1089/thy.2021.0565

FIG. 2.

FIG. 2.

Imaging of 124I avidity in Patient 4 at baseline and after combination vemurafenib plus CDX-3379. Baseline imaging of Patient 4 from the first 124I PET-CT lesional dosimetry showed no avidity in either the (A) thyroid bed, metastatic lymph node, or (B) lung metastases. Imaging from the second 124I PET-CT lesional dosimetry showed increased avidity after vemurafenib plus CDX-3379 in both the (C) thyroid bed, metastatic lymph node, and (D) lung metastases.